COVID-19 and pulmonary arterial hypertension (PAH) may share molecular mechanisms that could explain common disease-related features, a study reported. According to researchers, the findings provide a framework for exploring disease mechanisms and prioritizing future therapeutic strategies that target overlapping mechanisms of both conditions. The study, “Network-Based Multiomics Integration…
News
People with pulmonary arterial hypertension (PAH) have less diversity among the viruses that infect bacteria in their digestive tracts, according to a new study. These findings add to a growing body of research suggesting that the gut microbiome — the community of bacteria, viruses, and other microscopic organisms…
Once-daily use of Insmed‘s experimental inhaled treatment TPIP — fully, treprostinil palmitil inhalation powder — showed a range of benefits over one year in people with pulmonary arterial hypertension (PAH), a rare condition in which the blood vessels supplying the lungs become narrowed. That’s according to new 12-month…
Respiratory rehabilitation is safe and can help improve exercise capacity in people with chronic obstructive pulmonary disease (COPD) with or without pulmonary hypertension (PH), a study reported. A rehab program “demonstrated effectiveness in improving [exercise capacity] for COPD patients, regardless of the echocardiographic probability of PH,” the researchers…
Testing a pregnant woman’s levels of a protein linked to changes in the heart’s size and shape may help identify expectant mothers with pulmonary arterial hypertension (PAH) who are at high risk of serious complications after childbirth, a new study in China shows. The researchers found that levels of…
Corvista Health says a new billing code for use in the U.S., to take effect next year, will allow its noninvasive, point-of-care CorVista-PH test — used by clinicians to diagnose pulmonary hypertension (PH) — to be employed more widely, and earlier, to help identify people with heart-related conditions.
Most patients who completed one year in an open-label expanded access program (EAP) of CS1, an experimental oral treatment being developed by Cereno Scientific for pulmonary arterial hypertension (PAH), remained stable or improved on several clinical measures. The EAP (NCT06321705), also known as compassionate use, allowed patients…
Elevated blood levels of uric acid, a substance often associated with gout, are associated with a higher risk of pulmonary arterial hypertension (PAH) in people of European ancestry, a study suggested. “Our study supports a positive genetic association between [blood uric acid] and PAH risk,” the researchers wrote. “Further…
Blocking a signaling pathway in certain white blood cells may prevent blood clots from obstructing blood flow in the pulmonary arteries — the cause of chronic thromboembolic pulmonary hypertension (CTEPH). That’s according to a new study that investigated whether a certain immune signaling pathway in the body plays a…
Nine members of the pulmonary hypertension (PH) community have received awards for their support of the Pulmonary Hypertension Association (PHA). At the PHA 2026 International PH Conference and Scientific Sessions in Dallas, the community gathered to celebrate the recipients of this year’s member awards. “The Outstanding…
Oxiwear‘s wearable medical device, which continuously tracks oxygen levels in people with pulmonary hypertension (PH) and other heart or lung conditions, will now be covered by Medicare and certain private insurance providers in the U.S., the company announced. The…
Enrollment is complete in the Phase 2 APEX trial of TX45, Tectonic Therapeutic‘s experimental drug for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), the company reports. “Reaching full enrollment in our APEX Phase 2 clinical trial represents a critical milestone for our TX45 clinical development program…
